Home > Gastroenterology > ECCO 2022 > Short-Term and Long-Term Treatment Results > Vedolizumab first approved therapy for chronic pouchitis

Vedolizumab first approved therapy for chronic pouchitis

Presented By
Prof. Simon Travis, University of Oxford, UK

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ECCO 2022
Trial
Phase 4, EARNEST
Vedolizumab showed clinical, endoscopic, and histologic benefits over placebo in participants with chronic pouchitis after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). The safety profile of vedolizumab was consistent with previous data published on this agent. The phase 4 EARNEST trial is the first and largest randomised-controlled trial to demonstrate significant benefits of a biologic therapy in patients with chronic pouchitis. Prof. Simon Travis (University of Oxford, UK) explained that although antibiotics are the standard treatment for acute pouchitis, therapies for chronic antibiotic-refractory pouchitis are lacking [1]. Therefore, the double-blind, placebo-controlled EARNEST trial (NCT02790138) randomised participants with chronic pouchitis after proctocolectomy with IPAA for UC (n=102) 1:1 to vedolizumab (300 mg, intravenous, a...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on